Ultra-high speed AO-OCT clinical system to image ganglion cells and microglia

超高速 AO-OCT 临床系统对神经节细胞和小胶质细胞进行成像

• 批准号: 10547181
• 负责人: Mircea Mujat
• 金额: $ 87.56万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10547181
• 关键词: Area; Biological Markers; Blindness; Buffers; Cells; Clinical; Collaborations; Communities; Data; Degenerative Disorder; Detection; Development; Diabetes Mellitus; Diabetic Retinopathy; Diagnosis; Disease; Disease Marker; Disease Progression; Ear; Elements; Evaluation; Eye; Ganglia; Glaucoma; Goals; Government; Human; Image; Imaging Techniques; Investigation; Label; Lateral; Lead; Legal patent; Market Research; Massachusetts; Microglia; Monitor; Morphologic artifacts; Motion; Nerve Fibers; Neurosciences; Noise; Ophthalmology; Ophthalmoscopes; Optics; Pathogenesis; Patients; Performance; Persons; Phagocytosis; Pharmacotherapy; Phase; Play; Recording of previous events; Research; Resolution; Retina; Retinal Degeneration; Retinal Diseases; Retinal Ganglion Cells; Role; Scanning; Severity of illness; Signal Transduction; Source; Spatial Distribution; Speed; Structure; System; Technology; Testing; Time; Vision; adaptive optics; axon injury; base; clinical diagnostics; clinical imaging; cost; density; design; diagnostic platform; experience; ganglion cell; healthy volunteer; human subject; imager; imaging approach; imaging platform; imaging system; improved; improved functioning; innovation; instrument; interest; lens; macrophage; next generation; novel; novel therapeutics; optical imaging; physical science; programs; prototype; retinal imaging; routine imaging; specific biomarkers; tool

Project Summary/Abstract There is currently a significant need for new imaging techniques that may enable accurate quantification of biomarkers for detection, diagnosis, and monitoring of retinal diseases progression. Physical Sciences Inc. (PSI), Massachusetts Eye and Ear (MEE), and Joslin Diabetes Center (JDC) propose to develop a clinical tool able to routinely image retinal ganglion cells (RGCs) and to characterize microglia spatial distribution and temporal dynamics in live human eyes using a label-free adaptive optics (AO) imaging approach for improved diagnosis and treatment of glaucoma and diabetic retinopathy (DR). An ultra-high speed AO-OCT system will be designed and built based on a number of recently demonstrated innovations: lens-based design, ultra-high speed to eliminate motion artifacts, buffered swept source (SS) and dual beam approach to increase A-line rate to the MHz range, adaptive lens, dual-axis MEMS for raster scanning, and the use of polarization optics to eliminate specular reflections on optical elements. The retinal imager will be tested in a clinical setting at MEE and JDC on a large group of glaucoma and DR subjects experiencing a wide range of disease severity. Specific biomarkers for glaucoma and DR will be defined based on patient data acquired by our collaborators from MEE and JDC. PSI has a long, successful history of developing and commercializing high-resolution retinal imagers for the ophthalmic research market which gives us a competitive advantage in developing and maturing this platform that enables routine clinical imaging of human subjects and motivates a Direct to Phase II approach. A successful program and subsequent Phase III commercial development will provide clinicians with high performance retinal imaging for glaucoma and DR investigations at a lower cost and improved functionality superior to other non-AO retinal imagers. Early adaptors of this technology within the research community will grow our understanding of vision and its disruption by glaucoma and DR and will investigate the effects of new drugs and therapies. The ability to visualize ganglion and macrophage cells without fluorescent labeling in the human eye represents an important advance for both ophthalmology and neuroscience, which will lead to identification of novel disease biomarkers and new avenues of exploration in disease progression.

项目摘要/摘要 目前对新的成像技术的需求很大，这种技术可以实现准确的 用于检测、诊断和监测视网膜疾病进展的生物标志物的量化。 物理科学公司(PSI)、马萨诸塞州眼耳(MEE)和乔斯林糖尿病中心(JDC) 建议开发一种临床工具，能够常规地对视网膜神经节细胞(RGC)进行成像并表征 应用无标记自适应光学技术研究活体人眼小胶质细胞的空间分布和时间动力学 (Ao)改进青光眼和糖尿病视网膜病变(DR)诊断和治疗的成像方法。 超高速声光OCT系统将在最近几年的基础上设计和建造 展示的创新：基于镜头的设计，消除运动伪影的超高速，缓冲扫描 源(SS)和双波束方法将A线速率提高到MHz范围，自适应透镜，双轴 用于栅格扫描的MEMS，以及使用偏振光学来消除光学系统上的镜面反射 元素。视网膜成像仪将在MEE和JDC的临床环境中进行测试，对象是一大群 青光眼和DR受试者经历了广泛的疾病严重程度。青光眼的特异性生物标志物 DR将基于我们的合作者从MEE和JDC获得的患者数据来定义。 PSI在开发和商业化高分辨率视网膜成像仪方面有着悠久而成功的历史 眼科研究市场，使我们在开发和成熟这方面具有竞争优势 支持对人体受试者进行常规临床成像并激励直接进入第二阶段的平台 接近。一个成功的计划和随后的第三阶段商业开发将为临床医生提供 以更低的成本和改进的高性能视网膜成像用于青光眼和DR的研究 功能优于其他非声光视网膜成像仪。这项研究中这项技术的早期适配者 社区将加深我们对视力及其因青光眼和DR造成的破坏的了解，并将调查 新药和疗法的效果。在没有神经节和巨噬细胞的情况下 人眼中的荧光标记代表着眼科和眼科的重要进步 神经科学，这将导致识别新的疾病生物标记物和新的探索途径 在疾病的发展过程中。